{"entity":{"id":"nct04956640","kind":"trial","name":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","aka":[],"tldr":"A phase 1/2 trial of Olomorasib, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin and Carboplatin in non-small-cell lung cancer, colorectal cancer, endometrial cancer, ovarian cancer, pancreatic ductal adenocarcinoma and biliary tract cancer, run by Eli Lilly and Company, active and no longer recruiting.","summary":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) is a phase 1/2 interventional study registered as NCT04956640 by Eli Lilly and Company, with 540 participants enrolled, started 2021-07-19 and due to reach its primary completion in 2027-04. Interventions recorded: LY3537982, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin and Carboplatin.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04956640","url":"https://clinicaltrials.gov/study/NCT04956640"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","colorectal","endometrial","ovarian","pancreatic","cholangiocarcinoma","kras-g12c-colorectal","kras-g12c-nsclc","kras-g12c-pdac"],"sections":[],"technologies":["kras-inhibitors"],"targets":[],"drugs":["olomorasib","pembrolizumab","cetuximab","pemetrexed","cisplatin","carboplatin"],"companies":["eli-lilly","merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct04956640-nat-commun-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04956640","phase":"1/2","setting":"A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors","sponsor":"Eli Lilly and Company","started":"2021-07-19","startedType":"actual","enrolled":540,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04956640/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"kras-g12c-colorectal","kind":"cancer","name":"KRAS G12C-mutant colorectal cancer","route":"/cancers/kras-g12c-colorectal/"},{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/"},{"id":"kras-g12c-pdac","kind":"cancer","name":"KRAS G12C-mutant pancreatic ductal adenocarcinoma","route":"/cancers/kras-g12c-pdac/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"olomorasib","kind":"drug","name":"Olomorasib","route":"/drugs/olomorasib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}],"paper":[{"id":"paper-nct04956640-nat-commun-2026","kind":"paper","name":"Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study","route":"/key-papers/paper-nct04956640-nat-commun-2026/"}]}}